Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Matthew Ingham(Columbia University), Martee L. Hensley(Memorial Sloan Kettering Cancer Center), Stephanie Berg(Loyola University Medical Center), Suzanne George(Dana-Farber Cancer Institute), Brian Andrew Van Tine(Washington University in St. Louis), Sumithra J. Mandrekar(Mayo Clinic), Jacob B. Allred(Mayo Clinic), Gary K. Schwartz(Baylor University Medical Center)
Cited by 2
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725